Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more ...

The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

Hims shares logged their best session in a month and added after-hours gains. ・Novo expanded oral Wegovy access, while Citi ...

Hims & Hers is achieving tremendous revenue growth with a renewed Novo Nordisk weight loss partnership. Click here to read an ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.45, moving +2.12% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.62%. At the same time, ...

The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales, X-ray results, sugary sodas, a pie in the ...

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...

A short squeeze occurs when a stock's price rises unexpectedly, forcing short sellers (who are now losing money) to ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has recently announced its Q1 financial results, showing notable year-over-year growth. The company reported adjusted earnings per share of ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims & Hers' ...

Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo ...